Neoantigen based personalized immuno-oncology drugs are a relatively new therpauetic avenue that have shown strong anti-tumor efficacy in the clinic. Neoantigen peptides have been widely reported to be difficult to synthesize due to their hydrophobicity, length, and charge. Leveraging extensive peptide synthesis experience GenScript has developed NeoPre™, a predictive algorithm which is able to determine peptide synthesis difficulty based on sequence alone. NeoPre™ can then recommend the most efficient approach to successfully synthesizing peptides using one of GenScript's many synthesis platforms.